All News Compugen Ltd. TEL AVIV STOCK EXCHANGE

Equities

CGEN

IL0010852080

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 05:39:42 17/07/2024 pm IST			5-day change	1st Jan Change
680.7 ^ILa	-1.59%		+7.13%	-1.06%

27/06	Transcript : Compugen Ltd. - Special Call
30/05	Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Compugen Ltd. - Special Call	27/06
Compugen to Present at Upcoming Antibody Industrial Symposium	17/06	PR
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	30/05	PR
Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	30/05	CI
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating	20/05	MT
Compugen : Reports First Quarter 2024 Results	20/05	PU
Transcript : Compugen Ltd., Q1 2024 Earnings Call, May 20, 2024	20/05
Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, vs. Street Est of $1.2M	20/05	MT
Compugen: Q1 Earnings Snapshot	20/05	AQ
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	20/05	CI
Compugen Reports First Quarter 2024 Results	20/05	PR
Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	16/05	PU
Compugen Names David Silberman CFO	15/05	MT
Compugen Appoints David Silberman as Chief Financial Officer	15/05	PR
Compugen Ltd. Announces CFO Changes, Effective August 15, 2024	15/05	CI
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	06/05	PR
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	26/04	AQ
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	25/04	PU
Compugen to Participate in Two Upcoming Investor Conferences	03/04	PR
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	11/03	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Compugen Ltd. TEL AVIV STOCK EXCHANGE

Equities

CGEN

IL0010852080

All News

Filters